Published in PLoS One on July 05, 2012
High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli. Microb Cell Fact (2013) 0.84
Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody. Retrovirology (2014) 0.78
HIV-Nef and ADAM17-Containing Plasma Extracellular Vesicles Induce and Correlate with Immune Pathogenesis in Chronic HIV Infection. EBioMedicine (2016) 0.77
Selection of intracellular single-domain antibodies targeting the HIV-1 Vpr protein by cytoplasmic yeast two-hybrid system. PLoS One (2014) 0.76
The clinical potential of circulating tumor cells; the need to incorporate a modern "immunological cocktail" in the assay. Cancers (Basel) (2013) 0.76
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Assembly of cell regulatory systems through protein interaction domains. Science (2003) 10.59
Engineered antibody fragments and the rise of single domains. Nat Biotechnol (2005) 6.96
Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature (1989) 5.23
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature (1997) 4.26
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A (2000) 3.77
Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol (2005) 3.67
Designing customized cell signalling circuits. Nat Rev Mol Cell Biol (2010) 2.64
Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A (1995) 2.41
Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol (2009) 2.41
Single domain camel antibodies: current status. J Biotechnol (2001) 2.24
Domain antibodies: proteins for therapy. Trends Biotechnol (2003) 2.15
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol (2005) 1.99
Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Anal Biochem (1996) 1.94
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol (2009) 1.94
Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol (2008) 1.90
Biophysical properties of human antibody variable domains. J Mol Biol (2003) 1.80
New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology (1997) 1.61
Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol (2008) 1.57
The SH3 domain--a family of versatile peptide- and protein-recognition module. Front Biosci (2008) 1.52
SH3-Domain binding function of HIV-1 Nef is required for association with a PAK-related kinase. Virology (1998) 1.49
Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J (2008) 1.46
Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol (2007) 1.41
Design of protein function leaps by directed domain interface evolution. Proc Natl Acad Sci U S A (2008) 1.39
Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel (2008) 1.34
The HIV-1 pathogenicity factor Nef interferes with maturation of stimulatory T-lymphocyte contacts by modulation of N-Wasp activity. J Biol Chem (2006) 1.25
Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol (2005) 1.24
Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem (2004) 1.18
DARPins: a new generation of protein therapeutics. Drug Discov Today (2008) 1.17
Breaking the affinity ceiling for antibodies and T cell receptors. Proc Natl Acad Sci U S A (2000) 1.12
High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol (1995) 1.12
Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. Biochim Biophys Acta (2003) 1.02
Conformation of the dileucine-based sorting motif in HIV-1 Nef revealed by intermolecular domain assembly. Traffic (2011) 1.02
mAbs: a business perspective. MAbs (2009) 1.01
SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef. J Mol Biol (1999) 1.01
The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing. Methods Mol Biol (2010) 0.99
In vitro folding and thermodynamic stability of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm. J Mol Biol (1999) 0.99
Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood (2011) 0.95
Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef. PLoS One (2011) 0.94
Nanobodies®: proficient tools in diagnostics. Expert Rev Mol Diagn (2010) 0.93
Engineering antibodies for stability and efficient folding. Handb Exp Pharmacol (2008) 0.92
Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol (1996) 0.91
Inhibition of cellular functions of HIV-1 Nef by artificial SH3 domains. Virology (2001) 0.90
A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem (2006) 0.88
Implications of SH3 domain structure and dynamics for protein regulation and drug design. Cell Biochem Biophys (2001) 0.83
Versatile retargeting of SH3 domain binding by modification of non-conserved loop residues. FEBS Lett (2007) 0.82
Capacity of simian immunodeficiency virus strain mac Nef for high-affinity Src homology 3 (SH3) binding revealed by ligand-tailored SH3 domains. J Gen Virol (2002) 0.77
FMNL2 drives actin-based protrusion and migration downstream of Cdc42. Curr Biol (2012) 2.18
The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe (2011) 2.05
Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res (2007) 2.02
Structures of the dual bromodomains of the P-TEFb-activating protein Brd4 at atomic resolution. J Biol Chem (2009) 1.96
Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe (2008) 1.94
The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem (2003) 1.93
The human formin FHOD1 contains a bipartite structure of FH3 and GTPase-binding domains required for activation. Structure (2008) 1.85
The RNA polymerase II carboxy-terminal domain (CTD) code. Chem Rev (2013) 1.82
Uncovering the mysteries of hantavirus infections. Nat Rev Microbiol (2013) 1.75
High-throughput phosphotyrosine profiling using SH2 domains. Mol Cell (2007) 1.72
Identification of a cyclin T-binding domain in Hexim1 and biochemical analysis of its binding competition with HIV-1 Tat. J Biol Chem (2005) 1.71
The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology (2005) 1.67
HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog (2006) 1.67
Beta2 integrin phosphorylation on Thr758 acts as a molecular switch to regulate 14-3-3 and filamin binding. Blood (2008) 1.66
Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem (2002) 1.66
Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci U S A (2010) 1.60
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol (2008) 1.58
Fifteen formins for an actin filament: a molecular view on the regulation of human formins. Biochim Biophys Acta (2010) 1.56
Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. Nat Commun (2012) 1.49
Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J Biol Chem (2004) 1.47
Enterohaemorrhagic Escherichia coli exploits a tryptophan switch to hijack host f-actin assembly. Structure (2012) 1.47
Insulin receptor tyrosine kinase substrate links the E. coli O157:H7 actin assembly effectors Tir and EspF(U) during pedestal formation. Proc Natl Acad Sci U S A (2009) 1.46
Acetylation of RNA polymerase II regulates growth-factor-induced gene transcription in mammalian cells. Mol Cell (2013) 1.40
Structural insights into the cyclin T1-Tat-TAR RNA transcription activation complex from EIAV. Nat Struct Mol Biol (2008) 1.36
Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux. J Infect Dis (2010) 1.34
Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome. EMBO Rep (2006) 1.33
SH3 domain-mediated recruitment of host cell amphiphysins by alphavirus nsP3 promotes viral RNA replication. PLoS Pathog (2011) 1.32
Biochemical characterization of the diaphanous autoregulatory interaction in the formin homology protein FHOD1. J Biol Chem (2005) 1.30
Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism. J Biol Chem (2003) 1.29
HIV-1 Nef membrane association depends on charge, curvature, composition and sequence. Nat Chem Biol (2009) 1.29
Localization of HIV-1 Vpr to the nuclear envelope: impact on Vpr functions and virus replication in macrophages. Retrovirology (2007) 1.27
Nef-induced alteration of the early/recycling endosomal compartment correlates with enhancement of HIV-1 infectivity. J Biol Chem (2004) 1.26
Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1. J Biol Chem (2002) 1.25
Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef. Biochemistry (2006) 1.24
Avian and 1918 Spanish influenza a virus NS1 proteins bind to Crk/CrkL Src homology 3 domains to activate host cell signaling. J Biol Chem (2007) 1.22
Specific and distinct determinants mediate membrane binding and lipid raft incorporation of HIV-1(SF2) Nef. Virology (2006) 1.21
The Diaphanous-related Formin FHOD1 associates with ROCK1 and promotes Src-dependent plasma membrane blebbing. J Biol Chem (2008) 1.20
Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway. J Immunol (2004) 1.16
HIV-1 Nef stabilizes the association of adaptor protein complexes with membranes. J Biol Chem (2002) 1.16
Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res (2005) 1.12
Conformational states of human rat sarcoma (Ras) protein complexed with its natural ligand GTP and their role for effector interaction and GTP hydrolysis. J Biol Chem (2010) 1.12
Cooperative binding of the class I major histocompatibility complex cytoplasmic domain and human immunodeficiency virus type 1 Nef to the endosomal AP-1 complex via its mu subunit. J Virol (2007) 1.12
Molecular priming of Lyn by GPVI enables an immune receptor to adopt a hemostatic role. Proc Natl Acad Sci U S A (2009) 1.12
Leucine-specific, functional interactions between human immunodeficiency virus type 1 Nef and adaptor protein complexes. J Virol (2005) 1.10
Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J Virol (2003) 1.09
Structure of the Cyclin T binding domain of Hexim1 and molecular basis for its recognition of P-TEFb. Proc Natl Acad Sci U S A (2007) 1.09
HIV-1 Nef interacts with inositol trisphosphate receptor to activate calcium signaling in T cells. J Exp Med (2002) 1.08
Modulation of cellular protein trafficking by human immunodeficiency virus type 1 Nef: role of the acidic residue in the ExxxLL motif. J Virol (2006) 1.08
Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology (2007) 1.08
A crucial role in cell spreading for the interaction of Abl PxxP motifs with Crk and Nck adaptors. J Cell Sci (2008) 1.06
Reciprocal regulation of SH3 and SH2 domain binding via tyrosine phosphorylation of a common site in CD3epsilon. J Immunol (2007) 1.05
Dystroglycan, Tks5 and Src mediated assembly of podosomes in myoblasts. PLoS One (2008) 1.05
Nef proteins from simian immunodeficiency virus-infected chimpanzees interact with p21-activated kinase 2 and modulate cell surface expression of various human receptors. J Virol (2004) 1.05
Interactions and oligomerization of hantavirus glycoproteins. J Virol (2010) 1.05
Biophysical analysis of the interaction of Rab6a GTPase with its effector domains. J Biol Chem (2008) 1.05
Further studies on hepatitis C virus NS5A-SH3 domain interactions: identification of residues critical for binding and implications for viral RNA replication and modulation of cell signalling. J Gen Virol (2005) 1.04
Recognition of tandem PxxP motifs as a unique Src homology 3-binding mode triggers pathogen-driven actin assembly. Proc Natl Acad Sci U S A (2010) 1.04
Modulation of cell spreading and cell-substrate adhesion dynamics by dystroglycan. J Cell Sci (2010) 1.03
Conformation of the dileucine-based sorting motif in HIV-1 Nef revealed by intermolecular domain assembly. Traffic (2011) 1.02
Autoimmune regulator induced changes in the gene expression profile of human monocyte-dendritic cell-lineage. Mol Immunol (2004) 1.01
Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. Mol Aspects Med (2010) 1.01
Dynamic interaction of HIV-1 Nef with the clathrin-mediated endocytic pathway at the plasma membrane. Traffic (2006) 1.00
Expression of complement factor H binding immunoevasion proteins in Borrelia garinii isolated from patients with neuroborreliosis. Eur J Immunol (2005) 1.00
FHOD1 coordinates actin filament and microtubule alignment to mediate cell elongation. Exp Cell Res (2005) 0.99
When the lymphocyte loses its clothes. Immunity (2003) 0.99
Hantavirus structure--molecular interactions behind the scene. J Gen Virol (2012) 0.98
The phospholipid scramblases 1 and 4 are cellular receptors for the secretory leukocyte protease inhibitor and interact with CD4 at the plasma membrane. PLoS One (2009) 0.98
Nef associates with p21-activated kinase 2 in a p21-GTPase-dependent dynamic activation complex within lipid rafts. J Virol (2004) 0.97
Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity. J Virol (2008) 0.97
HIV Nef, paxillin, and Pak1/2 regulate activation and secretion of TACE/ADAM10 proteases. Mol Cell (2013) 0.96
Interaction of propionylated and butyrylated histone H3 lysine marks with Brd4 bromodomains. Angew Chem Int Ed Engl (2010) 0.96
Human immunodeficiency virus type 1 Vpr modulates cellular expression of UNG2 via a negative transcriptional effect. J Virol (2009) 0.96
FHOD1 is a combined actin filament capping and bundling factor that selectively associates with actin arcs and stress fibers. J Cell Sci (2013) 0.96
Unmodified histone H3K4 and DNA-dependent protein kinase recruit autoimmune regulator to target genes. Mol Cell Biol (2012) 0.95
Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood (2011) 0.95
DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol Biol Cell (2009) 0.94
Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem (2006) 0.94
Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef. PLoS One (2011) 0.94
Clathrin-independent entry of baculovirus triggers uptake of E. coli in non-phagocytic human cells. PLoS One (2009) 0.93
Cyclin box structure of the P-TEFb subunit cyclin T1 derived from a fusion complex with EIAV tat. J Mol Biol (2007) 0.93
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and coreceptor binding sites of HIV-1 gp120. J Virol (2012) 0.93
Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe (2012) 0.92
Complex formation and light activation in membrane-embedded sensory rhodopsin II as seen by solid-state NMR spectroscopy. Structure (2010) 0.92
Attenuation of Semliki Forest virus neurovirulence by microRNA-mediated detargeting. J Virol (2012) 0.91
Farnesylation of the SNARE protein Ykt6 increases its stability and helical folding. J Mol Biol (2008) 0.91
Role of the Kaposi's sarcoma-associated herpesvirus K15 SH3 binding site in inflammatory signaling and B-cell activation. J Virol (2010) 0.91
The mechanism of tissue-restricted antigen gene expression by AIRE. J Immunol (2013) 0.90
NMR spectroscopic investigation of early events in IAPP amyloid fibril formation. Chembiochem (2009) 0.90
Human immunodeficiency virus type 1 KK26-27 matrix mutants display impaired infectivity, circularization and integration but not nuclear import. Virology (2005) 0.90
Vpr and its interactions with cellular proteins. Curr Top Microbiol Immunol (2009) 0.90